Literature DB >> 26280523

Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.

Sayed F Abdelwahab1,2,3, Zainab Zakaria4, Walaa R Allam4, Shaimaa Hamdy4, Mohamed A Mahmoud5, Maha Sobhy4, Eman Rewisha5, Imam Waked5.   

Abstract

Several host and viral factors affect the natural history of Hepatitis C Virus (HCV) infection. Interleukin 28B (IL28B).rs12979860 single nucleotide polymorphism (SNP) was found to predict viral clearance with and without therapy. Subjects with the CC (favorable) genotype of IL28B.rs12979860 were more likely to spontaneously clear the infection and respond favorably to therapy. These data suggest that subjects with the "favorable" CC genotype might have a lower viral load when compared to those with the "unfavorable" TT genotype. Therefore, we examined the effect of IL28B.rs12979860 SNP on HCV viral load and clearance among HCV-infected Egyptians. This cross sectional study was conducted on 375 HCV antibody-positive subjects. Detection and quantification of HCV-RNA was determined by RT-PCR. IL28B.rs12979860 genotyping was performed using SYBR green real-time PCR and specific primers. Of 375 HCV-antibody positive subjects, 239 (63.7%) had chronic HCV infection while the remaining 136 (36.3%) subjects had spontaneously cleared the virus. The frequency of IL28-B CC, CT, and TT genotypes among spontaneous resolvers were 54.4%, 39.0%, and 6.6% while among the chronically infected subjects, they were 31.4%, 49.8%, and 18.8%, respectively. As expected, IL28 genotype predicted spontaneous HCV clearance (p < 0.001). The average HCV viral loads were 1.5 ± 0.69 x 10(6), 0.62 ± 0.11 x 10(6) and 0.51 ± 0.14 x 10(6) IU/ml among chronic subjects with the IL28B.rs12979860 CC, CT and TT genotypes, respectively (p > 0.05). In conclusion, our results show that IL28B.rs12979860 genotype does not affect viral load among chronic HCV infected Egyptians. These findings further confirm the complexity of viral host interactions in determining HCV infection outcome.

Entities:  

Keywords:  Egypt; HCV; HCV RNA; Hepatitis C; Interferon lambda 3; Interleukin 28; Single-nucleotide polymorphism; Viral hepatitis; Viral load

Mesh:

Substances:

Year:  2015        PMID: 26280523     DOI: 10.1007/s00705-015-2555-3

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  5 in total

1.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Association between thrombocytopenia and the severity of Covid-19 infection among hospitalized Egyptian patients.

Authors:  Mohsen M El-Khaiat; Ayman M El-Lehlah; Manal A Kesheita; Mohamed Abdel-Samiee; Ahmed Abozaid Ahmed Teima
Journal:  Ann Med Surg (Lond)       Date:  2022-06-11

3.  Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis.

Authors:  Hamid Heidarian Miri; Pooria Fazeli; Mohammad Ali-Hassanzadeh; Peyman Bemani; Dieter Kabelitz; Kurosh Kalantar
Journal:  Arch Virol       Date:  2021-07-03       Impact factor: 2.574

4.  Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients.

Authors:  Azeem Mehmood Butt; Arsalan Jamil Raja; Shafiqa Siddique; Jahangir Sarwar Khan; Muhammad Shahid; Ghias-Un-Nabi Tayyab; Zahid Minhas; Muhammad Umar; Muhammad Idrees; Yigang Tong
Journal:  Sci Rep       Date:  2016-02-22       Impact factor: 4.379

5.  Role of resistin, IL-6 and NH2-terminal portion proBNP in the pathogenesis of cardiac disease in type 2 diabetes mellitus.

Authors:  Samar Ebrahim Ghanem; Mohamed Abdel-Samiee; Mohamed Hamdy Torky; Ahmed Gaafar; Somia Mokabel Mohamed; Ghada Mohamed Mohamed Salah Eldin; Samah Mohammed Awad; Karema A Diab; Dalia M ELsabaawy; Sania Ali Yehia; Hany Abdelbary Abdelaziz Elbasyouni; Amr Aly Elshormilisy
Journal:  BMJ Open Diabetes Res Care       Date:  2020-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.